Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2020 / N 3

Применение фиксированной комбинации валсартана с амлодипином при лечении больных артериальной гипертонией
О.Д. Остроумова, В.Н. Буторов, Н.А. Араблинский

References

1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal 2018 Sep;39(33):3021-104.
2. Shalnova SA, Deyev AD, Balanova JuA, Kapustina AV, Konstantinov VV, Muromtseva GA, Boytsov SA. Dynamics of arterial hypertension in Russia: is there any progress in prescribing antihypertensive therapy? 1993-2013 study results. Russian Heart Journal 2015;14(6):389-96 (In Russian).
3. Chazova IE, Shchernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension 2019;16(1):6-31 (In Russian).
4. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Scientific Reports 2018 Jun;8(1):9418.
5. Ministry of Healthcare of the Russian Federation; Russian Society of Cardiology. Clinical guidelines. Arterial hypertension in adults. ICD 10: I10/ I11/ I12/ I13/ I15. Year of approval (frequency of revision): 2020. ID: KR62 (In Russian).
6. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009 May;338:b1665.
7. Nedogoda SV, Sanina TN, Tsoma VV, Ledyaeva AA, Chumachek EV, Salasyuk AS, Vlasov DS, Bychkova OI. Optimal organ protection and blood pressure control with the single pill combination of lisinopril, amlodipine and indapamide in arterial hypertension. Rational Pharmacotherapy in Cardiology 2020;16(6):931-7 (In Russian).
8. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technology Assessment 2003;7(31):1-94.
9. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clinical Therapeutics 2001 Dec;23(12):1999-2010.
10. Wogen J, Kreilick ChA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. Journal of Managed Care Pharmacy 2003 Sep-Oct;9(5):424-9.
11. Mancia G, Parodi P, Merlino L, Corrao G. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. Journal of Hypertension 2011 May;29(5):1012-8.
12. State register of medicines of the Ministry of Healthcare of the Russian Federation. Available from: grls.rosminzdrav.ru Accessed 2021 Feb 25. (In Russian).
13. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet 2004 Jun;363(9426):2022-31.
14. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The New England Journal of Medicine 2003 Nov;349(20):1893-906.
15. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal 2005 Mar;149(3):548-57.
16. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. The New England Journal of Medicine 2001 Dec;345(23):1667-75.
17. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2018 Jan;39(2):119-77.
18. Peters S, Götting B, Trümmel M, Rust H, Brattström A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. The Journal of Invasive Cardiology 2001 Feb;13(2):93-7.
19. Weycker D, Edelsberg J, Vincze G, Kjeldsen SE, Jamerson K, Khan ZM, Oster G. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. Journal of Human Hypertension 2007 May;21(5):374-80.
20. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation 2002 Aug;106(6):672-8.
21. Hollenberg NK, Parving HH, Viberti G, Remuzzi G. American Heart Association 2006 (abstract). Abstract 426: the Diovan Reduction Of Proteinutria (DROP) study: albuminuria response to high-doses of valsartan in type 2 diabetes mellitus. Originally published 9 Jun 2018 Circulation 2006;114:II_61.
22. Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Pressure. Supplement 1997;1:47-51.
23. Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. Journal of Clinical Hypertension (Greenwich) 2002 Nov-Dec;4(6):424-32.
24. Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Pressure. Supplement 2003 Dec;2:29-34.
25. Fogari R, Preti P, Zoppi A, Corradi L, Pasotti C, Rinaldi A, Mugellini A. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. American Journal of Hypertension 2004 Jan;17(1):77-81.
26. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. European Journal of Clinical Pharmacology 2002 Jun;58(3):177-80.
27. Fogari R, Mugellin A, Zoppi A, Marasi G, Pasotti C, Poletti L, Rinaldi A, Preti P. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. European Journal of Clinical Pharmacology 2004 Feb;59(12):863-8.
28. Radchenko AD. Some aspects of dihydropyridine calcium antagonists in treatment of hypertension. Part 1. Arterial Hypertension 2013;5(31):81-98 (In Russian).
29. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004 Nov;292(18):2217-25.
30. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 Sep;102(13):1503-10.
31. Deanfield JE, Detry JM, Lichtlen PR, Magnani B, Sellier P, Thaulow E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-ischemia Program in Europe (CAPE Trial). Journal of the American College of Cardiology 1994 Nov;24(6):1460-7.
32. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. Journal of the American Society of Hypertension 2008 Jul-Aug;2(4):294-302.
33. Chazova IE, Karpov YuA, Vigdorchik AV on behalf of research group. Efficacy and safety of amlodipine and valsartan combination in treatment of arterial hypertension in clinical practice: first results of the Russian observational study EXTRA. Systemic Hypertension 2010;2:20-7 (In Russian).
34. Karpov YuA, Podzolkov VI, Fomin VV, Vigdorchik AV. Russian observational studies of valsartan and combined antihypertensive therapy based on it. Systemic Hypertension 2011;8(2):5-9 (In Russian).
35. Drugs for the heart. Opie LH, editor. 3rd ed. Philadelphia, Pa: WB Saunders; 1991: 42-73.
36. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. Journal of Cardiovascular Pharmacology 1987;10(Suppl 1):S121-31.
37. Ohman EM, Bhatt DL, Steg PG, Goto Sh, Hirsch AT, Liau ChS, Mas JL, Richard AJ, Röther J, Wilson PWF; REACH Registry Investigators. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. American Heart Journal 2006 Apr;151(4):786.e1-10.
38. Karpov YuA, Shalnova SA, Deyev AD. PREMIERE study: reaching target blood pressure level – a success in the coronary heart disease treatment. Cardiovascular Therapy and Prevention 2006;5(6):53-60 (In Russian).
39. Ministry of Healthcare of the Russian Federation; Russian Society of Cardiology. Clinical recommendations. Stable ischemic heart disease. ICD 10: I20. 0, I20. 1, I20. 8, I20. 9, I25.0, I25.1, I25.2, I25.3, I25.4, I25.5, I25.6, I25.8, I25.9. Age group: adults. Year of approval: 2020. ID: KR155/1 (In Russian).
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]